PROS1 and malaria: Among the QS-based vaccines shown to be safe and effective—including the vaccine against the varicella herpes zoster virus (Shingrix®, approved by the FDA); the vaccine against the malaria parasite Plasmodium falciparum (Mosquirix®, approved by the EMA); and the one recently authorized for emergency use against COVID-19 (NuvaxovidTM, NVX-CoV2373)—a vaccine has been proposed as an alternative to better deal with the evolved variants of SARS-CoV-2 (which are characterized by having multiple mutations in the RBD region of the S protein).